Abstract
Triple negative breast cancer (TNBC) makes up approximately 15%-20% of all breast cancers. There is currently no targeted therapy against TNBC. Oncolytic virotherapy, the use of viruses to eliminate cancer cells, is a promising strategy for targeted cancer therapy. Seneca Valley virus (SVV), a novel oncolytic virus, shows high affinity for tumours and no affinity for healthy tissue. The cellular receptor responsible for this affinity is anthrax toxin receptor 1 (ANTXR1) also known as tumour endothelial marker 8 (TEM8). TEM8 is present in over 60% of human solid cancers including TNBC and absent in healthy tissue. Clinical trials of SVV as a monotherapy have proven the safety of the treatment but yielded inconclusive results of therapeutic efficacy.